# Evaluate the Safety, Tolerability of BAT6026

> **NCT06094179** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bio-Thera Solutions** · enrollment: 33 (estimated)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Monoclonal antibody BAT6026
- **DRUG:** sodium chloride injection

## Key facts

- **NCT ID:** NCT06094179
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094179, "Evaluate the Safety, Tolerability of BAT6026". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06094179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*